Home > Publications database > Pleiotropic Effects of Metformin on the Chemotherapy Response of HPV-Positive Cancer Cells. > print

001     302113
005     20250805110400.0
024 7 _ |a 10.1002/jmv.70434
|2 doi
024 7 _ |a pmid:40522309
|2 pmid
024 7 _ |a pmc:PMC12169209
|2 pmc
024 7 _ |a 0146-6615
|2 ISSN
024 7 _ |a 1096-9071
|2 ISSN
037 _ _ |a DKFZ-2025-01245
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Avenhaus, Alicia
|0 P:(DE-He78)b99b271e0ad2dea9ba3ebefc35af9a76
|b 0
|e First author
|u dkfz
245 _ _ |a Pleiotropic Effects of Metformin on the Chemotherapy Response of HPV-Positive Cancer Cells.
260 _ _ |a Bognor Regis [u.a.]
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754384608_28894
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D365#LA:D365# Z999
520 _ _ |a Improved treatment strategies for HPV-positive cancers are urgently required. The viral E6/E7 oncoproteins are essential for the proliferation of HPV-positive cancer cells and considered attractive therapeutic targets. Metformin is proposed to be repurposed for cancer therapy, but this is under controversial debate. We previously demonstrated that E6/E7 expression and the proliferation of HPV-positive cancer cells are repressed by Metformin. Here, we explore the effects of Metformin on the phenotype of HPV-positive cancer cells in detail, either applied as monotreatment or in combination with chemotherapeutic agents. We provide evidence that the downregulation of E6/E7 is not the primary mechanism underlying Metformin's growth-inhibitory effect in HPV-positive cancer cells. Specifically, compared to targeted E6/E7 repression by RNA interference (RNAi), Metformin treatment differently altered the expression of growth regulatory proteins, exerted different effects on the cell cycle, and was able to suppress growth even in the presence of E6/E7. Furthermore, we found that cancer cells pre-treated with Metformin become resistant to senescence induction by the pro-senescent chemotherapeutic agent Etoposide, likely as a secondary effect of Metformin-induced growth inhibition. Finally, depending on experimental conditions, we uncover divergent, even opposing, effects on the proliferation of HPV-positive cancer cells when Metformin is combined with Cisplatin, with p53 playing a key role in these processes. Collectively, our results show that Metformin exerts complex effects on the phenotype of HPV-positive cancer cells, which are critically influenced by experimental conditions. Our findings may also explain the discrepant results in the literature, reporting agonistic or antagonistic effects upon combining Metformin with Cisplatin.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Metformin
|2 Other
650 _ 7 |a cervical cancer
|2 Other
650 _ 7 |a chemotherapy
|2 Other
650 _ 7 |a human papillomavirus (HPV)
|2 Other
650 _ 7 |a oncogenesis
|2 Other
650 _ 7 |a oncoproteins
|2 Other
650 _ 7 |a Metformin
|0 9100L32L2N
|2 NLM Chemicals
650 _ 7 |a Oncogene Proteins, Viral
|2 NLM Chemicals
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 7 |a Papillomavirus E7 Proteins
|2 NLM Chemicals
650 _ 7 |a Etoposide
|0 6PLQ3CP4P3
|2 NLM Chemicals
650 _ 2 |a Metformin: pharmacology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Oncogene Proteins, Viral: genetics
|2 MeSH
650 _ 2 |a Oncogene Proteins, Viral: metabolism
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Antineoplastic Agents: pharmacology
|2 MeSH
650 _ 2 |a Cell Proliferation: drug effects
|2 MeSH
650 _ 2 |a Papillomavirus Infections: virology
|2 MeSH
650 _ 2 |a Papillomavirus E7 Proteins: genetics
|2 MeSH
650 _ 2 |a Etoposide: pharmacology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
700 1 _ |a Kuhn, Bianca
|0 P:(DE-He78)ab6ac5c80adf172215f70d135c3fdc3f
|b 1
700 1 _ |a Velimirović, Milica
|0 P:(DE-He78)0a4c58c6737b30b65df3ed36acc08d4f
|b 2
|u dkfz
700 1 _ |a Strobel, Tobias
|0 P:(DE-He78)0dd31e782183886a3a3728cd5a97194d
|b 3
700 1 _ |a Bulkescher, Julia
|0 P:(DE-He78)c04ec6ab9480d74da506d656185ec7d2
|b 4
|u dkfz
700 1 _ |a Lohrey, Claudia
|0 P:(DE-He78)2ebb2998d182d99478108ef2cb4b804c
|b 5
|u dkfz
700 1 _ |a Krijgsveld, Jeroen
|0 P:(DE-He78)939d5891259c638c1ab053b1456a578c
|b 6
|u dkfz
700 1 _ |a Hoppe-Seyler, Felix
|0 P:(DE-He78)25779f8829ab7a7650e85a4cc871e6ac
|b 7
|u dkfz
700 1 _ |a Hoppe-Seyler, Karin
|0 P:(DE-He78)97468f1980416a4376b44e701d25f24b
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1002/jmv.70434
|g Vol. 97, no. 6, p. e70434
|0 PERI:(DE-600)1475090-9
|n 6
|p e70434
|t Journal of medical virology
|v 97
|y 2025
|x 0146-6615
909 C O |p VDB
|o oai:inrepo02.dkfz.de:302113
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)b99b271e0ad2dea9ba3ebefc35af9a76
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)ab6ac5c80adf172215f70d135c3fdc3f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)0a4c58c6737b30b65df3ed36acc08d4f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)0dd31e782183886a3a3728cd5a97194d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)c04ec6ab9480d74da506d656185ec7d2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)2ebb2998d182d99478108ef2cb4b804c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)939d5891259c638c1ab053b1456a578c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)25779f8829ab7a7650e85a4cc871e6ac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)97468f1980416a4376b44e701d25f24b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MED VIROL : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J MED VIROL : 2022
|d 2025-01-02
920 2 _ |0 I:(DE-He78)D365-20160331
|k D365
|l Molek. Therapie virusassozierter Tumore
|x 0
920 1 _ |0 I:(DE-He78)D365-20160331
|k D365
|l Molek. Therapie virusassozierter Tumore
|x 0
920 1 _ |0 I:(DE-He78)B230-20160331
|k B230
|l B230 Proteomik von Stammzellen und Krebs
|x 1
920 0 _ |0 I:(DE-He78)D365-20160331
|k D365
|l Molek. Therapie virusassozierter Tumore
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D365-20160331
980 _ _ |a I:(DE-He78)B230-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21